Cellectar Biosciences, Inc.
NASDAQ:CLRB
2.12 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.011 | 0.033 | 0.096 | 0.126 | 0 | 0 | 0.013 |
| Cost of Revenue
| 0.192 | 0.239 | 0.228 | 0.208 | 0.189 | 0.082 | 1.546 | 0.357 | 0.363 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.192 | -0.239 | -0.228 | -0.208 | -0.189 | -0.082 | -1.546 | -0.357 | -0.363 | 0 | 0 | 0 | -0.011 | 0.033 | 0.096 | 0.126 | 0 | 0 | 0.013 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 28.211 | 19.22 | 17.586 | 10.141 | 8.996 | 6.835 | 9.466 | 4.75 | 5.159 | 5.964 | 6.86 | 5.123 | 3.599 | 2.998 | 8.08 | 14.527 | 17.428 | 6.441 | 1.136 |
| General & Administrative Expenses
| 10.749 | 9.594 | 6.545 | 5.15 | 5.183 | 4.82 | 4.135 | 4.699 | 3.395 | 3.705 | 4.445 | 3.632 | 0 | 2.486 | 2.182 | 2.19 | 2.866 | 2.488 | 0 |
| Selling & Marketing Expenses
| -0.192 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.749 | 9.594 | 6.545 | 5.15 | 5.183 | 4.82 | 4.135 | 4.699 | 3.395 | 3.705 | 4.445 | 3.632 | 2.692 | 2.486 | 2.182 | 2.19 | 2.866 | 2.488 | 1.443 |
| Other Expenses
| -0 | 0 | 0.007 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 38.961 | 28.814 | 24.131 | 15.29 | 14.179 | 11.655 | 13.601 | 9.45 | 8.554 | 9.669 | 11.305 | 8.755 | 6.292 | 5.484 | 10.262 | 16.717 | 20.294 | 8.93 | 2.579 |
| Operating Income
| -38.961 | -28.814 | -24.131 | -15.29 | -14.179 | -13.331 | -13.601 | -9.45 | -8.758 | -9.891 | -12.402 | -8.755 | -7.038 | -5.451 | -10.166 | -16.591 | -20.294 | -8.93 | -5.088 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 639.793 | -163.517 | -105.552 | -131.708 | 0 | 0 | -404.283 |
| Total Other Income Expenses Net
| 0.917 | 0.153 | 0.009 | 0.196 | 0.086 | -1.613 | 0.022 | 3.262 | 3.06 | 2.009 | 0.532 | -0.034 | -0.714 | 7.544 | -12.108 | 0.009 | 0.007 | 0.006 | -0.428 |
| Income Before Tax
| -38.043 | -28.661 | -24.122 | -15.094 | -14.093 | -13.239 | -13.562 | -6.18 | -5.495 | -8.106 | -10.782 | -8.797 | -7.752 | -12.654 | -26.284 | -22.961 | -29.721 | -8.547 | -3.164 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 704.691 | -379.601 | -272.895 | -182.275 | 0 | 0 | -251.469 |
| Income Tax Expense
| 0.06 | -0.06 | -0.152 | -0.338 | -0.219 | -1.554 | -0.039 | -3.269 | -3.422 | -1.563 | -0.523 | 0.009 | 1.144 | -7.546 | 12.107 | -0.14 | -0.737 | -0.644 | 0.487 |
| Net Income
| -37.983 | -28.601 | -23.97 | -14.757 | -13.874 | -13.239 | -13.562 | -6.18 | -5.495 | -8.106 | -10.782 | -8.797 | -7.435 | 2.095 | -22.273 | -16.451 | -19.557 | -8.286 | -3.053 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 675.947 | 62.861 | -231.257 | -130.6 | 0 | 0 | -242.641 |
| EPS
| -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.7 | -96.66 | -141.54 | -702.78 | -1,765.33 | -3,859.04 | -4,278.68 | -6,211.71 | -31,022.2 | -1,012,423 | -1,175,100.43 | -1,629,761.25 | -690,504.67 | -254,449.92 |
| EPS Diluted
| -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.7 | -96.66 | -141.54 | -702.78 | -1,765.33 | -3,859.04 | -4,278.68 | -6,211.71 | -31,022.2 | -1,012,423 | -1,175,100.43 | -1,629,761.25 | -690,504.67 | -254,449.92 |
| EBITDA
| -38.768 | -28.814 | -24.131 | -15.476 | -14.222 | -9.96 | -12.077 | -12.355 | -11.614 | -11.311 | -11.412 | -8.257 | -4.993 | -12.959 | 1.974 | -16.583 | -20.286 | -8.926 | -2.135 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 453.89 | -388.762 | 20.499 | -131.646 | 0 | 0 | -169.687 |